Pluristem Therapeutics (PSTI) Preliminary COVID-19 Results a 'Game Changer' - H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $15.50 price target on Pluristem Therapeutics (NASDAQ: PSTI) saying today's strong preliminary COVID-19 results are a "game-changer."

Pluristem announced that six of the seven patients have completed the seven day follow up period and the preliminary data demonstrated 100% survival rate as of today.

For an analyst ratings summary and ratings history on Pluristem Therapeutics click here. For more ratings news on Pluristem Therapeutics click here.

Shares of Pluristem Therapeutics closed at $3.36 yesterday.

You May Also Be Interested In

• Humana (HUM) surges on Q1 beat, reiterated adjusted earnings outlook
• Summit Insights Downgrades Silicon Labs (SLAB) to Hold, 'expect its stock to be an inline performer'
• Boston Scientific (BSX) PT Raised to $83 at Stifel